Douglas E. Onsi
Chief Financial Officer @ Leap Therapeutics
Boston, United States
Douglas E. Onsi is a Series A investor at Leap Therapeutics in Boston focused on Health Care and Biotechnology. Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCareVentures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Douglas E. Onsi invests in
Stages Douglas E. Onsi invests in
Countries Douglas E. Onsi invests in
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Medical Device 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vaxxas
|
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $10.1M / Series A / Aug 02, 2011 |
Co-Investors
About Leap Therapeutics
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
Leap Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gus Lawlor
Chief Operating Officer
|
|||
Gus Lawlor
Chief Operating Officer
|
|||
|
Chris Mirabelli
President & CEO
|
|||
Cyndi Sirard
Chief Medical Officer
|
|||
|
Douglas E. Onsi
Chief Financial Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Douglas E. Onsi invest in?
Douglas E. Onsi invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Douglas E. Onsi last invest?
The most recent investment recorded for Douglas E. Onsi closed in Aug 2011. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
